191 related articles for article (PubMed ID: 19560921)
1. Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors.
Sablone MR; Cesta MC; Moriconi A; Aramini A; Bizzarri C; Di Giacinto C; Di Bitondo R; Gloaguen I; Aschi M; Crucianelli M; Bertini R; Allegretti M
Bioorg Med Chem Lett; 2009 Aug; 19(15):4026-30. PubMed ID: 19560921
[TBL] [Abstract][Full Text] [Related]
2. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
Moriconi A; Cesta MC; Cervellera MN; Aramini A; Coniglio S; Colagioia S; Beccari AR; Bizzarri C; Cavicchia MR; Locati M; Galliera E; Di Benedetto P; Vigilante P; Bertini R; Allegretti M
J Med Chem; 2007 Aug; 50(17):3984-4002. PubMed ID: 17665889
[TBL] [Abstract][Full Text] [Related]
3. 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
Allegretti M; Bertini R; Cesta MC; Bizzarri C; Di Bitondo R; Di Cioccio V; Galliera E; Berdini V; Topai A; Zampella G; Russo V; Di Bello N; Nano G; Nicolini L; Locati M; Fantucci P; Florio S; Colotta F
J Med Chem; 2005 Jun; 48(13):4312-31. PubMed ID: 15974585
[TBL] [Abstract][Full Text] [Related]
4. Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.
Aki C; Chao J; Ferreira JA; Dwyer MP; Yu Y; Chao J; Merritt RJ; Lai G; Wu M; Hipkin RW; Fan X; Gonsiorek W; Fosseta J; Rindgen D; Fine J; Lundell D; Taveras AG; Biju P
Bioorg Med Chem Lett; 2009 Aug; 19(15):4446-9. PubMed ID: 19525110
[TBL] [Abstract][Full Text] [Related]
5. 3-(Imidazolyl methyl)-3-aza-bicyclo[3.1.0]hexan-6-yl)methyl ethers: a novel series of mGluR2 positive allosteric modulators.
Zhang L; Rogers BN; Duplantier AJ; McHardy SF; Efremov I; Berke H; Qian W; Zhang AQ; Maklad N; Candler J; Doran AC; Lazzaro JT; Ganong AH
Bioorg Med Chem Lett; 2008 Oct; 18(20):5493-6. PubMed ID: 18812259
[TBL] [Abstract][Full Text] [Related]
6. Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors.
Orvieto F; Branca D; Giomini C; Jones P; Koch U; Ontoria JM; Palumbi MC; Rowley M; Toniatti C; Muraglia E
Bioorg Med Chem Lett; 2009 Aug; 19(15):4196-200. PubMed ID: 19541484
[TBL] [Abstract][Full Text] [Related]
7. 3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimization.
Duplantier AJ; Efremov I; Candler J; Doran AC; Ganong AH; Haas JA; Hanks AN; Kraus KG; Lazzaro JT; Lu J; Maklad N; McCarthy SA; O'Sullivan TJ; Rogers BN; Siuciak JA; Spracklin DK; Zhang L
Bioorg Med Chem Lett; 2009 May; 19(9):2524-9. PubMed ID: 19328692
[TBL] [Abstract][Full Text] [Related]
8. C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.
Chao J; Taveras AG; Chao J; Aki C; Dwyer M; Yu Y; Purakkattle B; Rindgen D; Jakway J; Hipkin W; Fosetta J; Fan X; Lundell D; Fine J; Minnicozzi M; Phillips J; Merritt JR
Bioorg Med Chem Lett; 2007 Jul; 17(13):3778-83. PubMed ID: 17459706
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach.
Ueda S; Kato M; Inuki S; Ohno H; Evans B; Wang ZX; Peiper SC; Izumi K; Kodama E; Matsuoka M; Nagasawa H; Oishi S; Fujii N
Bioorg Med Chem Lett; 2008 Jul; 18(14):4124-9. PubMed ID: 18539453
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel 2-pyridone peptidomimetic falcipain 2/3 inhibitors.
Verissimo E; Berry N; Gibbons P; Cristiano ML; Rosenthal PJ; Gut J; Ward SA; O'Neill PM
Bioorg Med Chem Lett; 2008 Jul; 18(14):4210-4. PubMed ID: 18554905
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors.
Siu T; Liang J; Arruda J; Li Y; Jones RE; Defeo-Jones D; Barnett SF; Robinson RG
Bioorg Med Chem Lett; 2008 Jul; 18(14):4186-90. PubMed ID: 18539456
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and structure-activity relationship of novel CCR2 antagonists.
Kothandaraman S; Donnely KL; Butora G; Jiao R; Pasternak A; Morriello GJ; Goble SD; Zhou C; Mills SG; Maccoss M; Vicario PP; Ayala JM; Demartino JA; Struthers M; Cascieri MA; Yang L
Bioorg Med Chem Lett; 2009 Mar; 19(6):1830-4. PubMed ID: 19237282
[TBL] [Abstract][Full Text] [Related]
13. The identification of potent, selective, and bioavailable cathepsin S inhibitors.
Gauthier JY; Black WC; Courchesne I; Cromlish W; Desmarais S; Houle R; Lamontagne S; Li CS; Massé F; McKay DJ; Ouellet M; Robichaud J; Truchon JF; Truong VL; Wang Q; Percival MD
Bioorg Med Chem Lett; 2007 Sep; 17(17):4929-33. PubMed ID: 17590332
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and SAR of tolylamine 5-HT6 antagonists.
Singer JM; Wilson MW; Johnson PD; Graham SR; Cooke LW; Roof RL; Boxer PA; Gold LH; Meltzer LT; Janssen A; Roush N; Campbell JE; Su TZ; Hurst SI; Stoner CL; Schwarz JB
Bioorg Med Chem Lett; 2009 May; 19(9):2409-12. PubMed ID: 19346128
[TBL] [Abstract][Full Text] [Related]
15. 4-Phenyl-7-azaindoles as potent and selective IKK2 inhibitors.
Liddle J; Bamborough P; Barker MD; Campos S; Cousins RP; Cutler GJ; Hobbs H; Holmes DS; Ioannou C; Mellor GW; Morse MA; Payne JJ; Pritchard JM; Smith KJ; Tape DT; Whitworth C; Williamson RA
Bioorg Med Chem Lett; 2009 May; 19(9):2504-8. PubMed ID: 19349179
[TBL] [Abstract][Full Text] [Related]
16. Computational studies of CXCR1, the receptor of IL-8/CXCL8, using molecular dynamics and electrostatics.
Huynh N; Mallik B; Zhang L; Martins-Green M; Morikis D
Biopolymers; 2008 Jan; 89(1):52-61. PubMed ID: 17876799
[TBL] [Abstract][Full Text] [Related]
17. Recent progress in the development of allosteric modulators of mGluR5.
Rodriguez AL; Williams R
Curr Opin Drug Discov Devel; 2007 Nov; 10(6):715-22. PubMed ID: 17987523
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel class of 2-mercaptohexanoic acid derivatives as highly active PPARalpha agonists.
Zettl H; Steri R; Lämmerhofer M; Schubert-Zsilavecz M
Bioorg Med Chem Lett; 2009 Aug; 19(15):4421-6. PubMed ID: 19556125
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.
Yu Y; Dwyer MP; Chao J; Aki C; Chao J; Purakkattle B; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Qiu H; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; He Z; Lai G; Wu M; Taveras A
Bioorg Med Chem Lett; 2008 Feb; 18(4):1318-22. PubMed ID: 18242983
[TBL] [Abstract][Full Text] [Related]
20. 'Reverse' alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Oct; 18(20):5456-9. PubMed ID: 18835164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
